Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03771157 · ClinicalTrials.gov registry record · Early Phase 1
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
A Early Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinemia (WM), sponsored by University of Rochester.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03771157 is a Early Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinemia (WM) that has completed, run by University of Rochester. The registered enrollment target is 33 participants, below the 190-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03771157, a Early Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinemia (WM), has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.
Conditions Studied
Interventions
- DRUG Shingrix vaccine
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2022-08-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03771157
The ClinicalTrials.gov registry entry for NCT03771157 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (83% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which Shingrix vaccine is the first listed.
NCT03771157 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03771157 about?
NCT03771157 is a clinical study titled "Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors". The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.
What is the current status of trial NCT03771157?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 33 participants. The study started on 2019-02-01. Estimated completion is 2022-08-03.
What conditions does trial NCT03771157 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM).
What interventions are being tested in trial NCT03771157?
The interventions under investigation include: Shingrix vaccine (DRUG).
Who is sponsoring clinical trial NCT03771157?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03771157 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
RECRUITING · Early Phase 1
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
Explore more on PlainTrial
Chronic Lymphocytic Leukemia (CLL)
All registered trials for this condition
Waldenstrom Macroglobulinemia (WM)
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.